Overview

Safety and Efficacy of YHD001 in Asthma

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

The main objective is to evaluate the safety/tolerability and efficacy of YHD001 compared to singulair or placebo in patients (n=96) with partially controlled asthma. The study will conduct with 4 comparative groups orally treated with YHD001 dose level 1(t.i.d.), YHD001 dose level 2(t.i.d.), singulair 10mg(q.d.) or Placebo for 8 weeks.

Phase:

Phase 2

Details

Lead Sponsor:

Yuhan Corporation

Treatments:

Montelukast